Lissamine Green in Ophthalmology: A Comprehensive Review of Diagnostic and Clinical Applications.

IF 2.6 3区医学 Q2 OPHTHALMOLOGY

Ophthalmology and Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-05 DOI:10.1007/s40123-025-01168-1

Stefano Barabino, Pasquale Aragona, Stefano Bonini, Emilia Cantera, Antonio Di Zazzo, Giuseppe Giannaccare, Andrea Leonardi, Giancarlo Montani, Alessandro Mularoni, Vincenzo Orfeo, Edoardo Villani, Fabrizio Zeri, Maurizio Rolando

{"title":"Lissamine Green in Ophthalmology: A Comprehensive Review of Diagnostic and Clinical Applications.","authors":"Stefano Barabino, Pasquale Aragona, Stefano Bonini, Emilia Cantera, Antonio Di Zazzo, Giuseppe Giannaccare, Andrea Leonardi, Giancarlo Montani, Alessandro Mularoni, Vincenzo Orfeo, Edoardo Villani, Fabrizio Zeri, Maurizio Rolando","doi":"10.1007/s40123-025-01168-1","DOIUrl":null,"url":null,"abstract":"<p><p>Lissamine green (LG), a diagnostic dye that stains devitalized or damaged epithelial cells, is widely used to assess ocular surface integrity, enabling the detection of inflammation, epithelial defects, and conjunctival irregularities. To explore the diagnostic and clinical applications of LG in ophthalmology, focusing on its use for ocular surface diseases, a group of experts in ophthalmology and optometry participated in an advisory board to share their clinical practice experience with the use of LG. Building on the advisory board contents, this narrative review was based on a combination of expert opinions from the roundtable discussion and a comprehensive review of the current literature. This review highlights the clinical relevance of LG as a diagnostic tool in ocular surface disease and underscores the potential of newer formulations to enhance diagnostic accuracy. In particular, the review highlights the historical development of LG use in ophthalmology and its advantages over other dyes, especially in terms of patient comfort and safety, as well as specific clinical protocols for using LG in assessing dry eye disease severity and inflammatory responses. Additionally, the review examines recent advancements in LG formulations, which enhance their utility in clinical practice, and addresses safety considerations. Potential areas for future research are also discussed, particularly in developing standardized evaluation procedures using artificial intelligence.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"1649-1660"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271041/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40123-025-01168-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lissamine green (LG), a diagnostic dye that stains devitalized or damaged epithelial cells, is widely used to assess ocular surface integrity, enabling the detection of inflammation, epithelial defects, and conjunctival irregularities. To explore the diagnostic and clinical applications of LG in ophthalmology, focusing on its use for ocular surface diseases, a group of experts in ophthalmology and optometry participated in an advisory board to share their clinical practice experience with the use of LG. Building on the advisory board contents, this narrative review was based on a combination of expert opinions from the roundtable discussion and a comprehensive review of the current literature. This review highlights the clinical relevance of LG as a diagnostic tool in ocular surface disease and underscores the potential of newer formulations to enhance diagnostic accuracy. In particular, the review highlights the historical development of LG use in ophthalmology and its advantages over other dyes, especially in terms of patient comfort and safety, as well as specific clinical protocols for using LG in assessing dry eye disease severity and inflammatory responses. Additionally, the review examines recent advancements in LG formulations, which enhance their utility in clinical practice, and addresses safety considerations. Potential areas for future research are also discussed, particularly in developing standardized evaluation procedures using artificial intelligence.

查看原文本刊更多论文

丽丝胺绿在眼科中的诊断和临床应用综述。

丽丝胺绿（LG）是一种用于染色失活或受损上皮细胞的诊断染料，被广泛用于评估眼表完整性，能够检测炎症、上皮缺陷和结膜不规则。为了探讨LG在眼科的诊断和临床应用，重点是其在眼表疾病中的应用，一组眼科和验光专家参加了一个顾问委员会，分享了他们使用LG的临床实践经验。在咨询委员会内容的基础上，这篇叙述性综述结合了圆桌讨论的专家意见和对当前文献的全面综述。本综述强调了LG作为眼表疾病诊断工具的临床相关性，并强调了新配方提高诊断准确性的潜力。该综述特别强调了LG在眼科应用的历史发展及其相对于其他染料的优势，特别是在患者舒适度和安全性方面，以及使用LG评估干眼病严重程度和炎症反应的具体临床方案。此外，该审查审查了LG配方的最新进展，这些进展增强了其在临床实践中的效用，并解决了安全性问题。还讨论了未来研究的潜在领域，特别是在使用人工智能开发标准化评估程序方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmology and Therapy OPHTHALMOLOGY-

CiteScore

4.20

自引率

3.00%

发文量

157

审稿时长

6 weeks

期刊介绍： Aims and Scope Ophthalmology and Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from preclinical, clinical (all phases), observational, real-world, and health outcomes research around the use of ophthalmological therapies, devices, and surgical techniques. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Ophthalmology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. Rapid Publication The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of ophthalmic therapies. Open Access All articles published by Ophthalmology and Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. Digital Features and Plain Language Summaries Ophthalmology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website. Please follow the link for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Ophthalmology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.